Engineering switchable and programmable universal CARs for CAR T therapy

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

(2019) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Increasing T Cell Versatility with SUPRA CARs

(2018) Yvonne Y. Chen   CELL

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

(2018) David Porter et al.   Journal of Hematology & Oncology

Gcn4 Binding in Coding Regions Can Activate Internal and Canonical 5′ Promoters in Yeast

(2018) Yashpal Rawal et al.   MOLECULAR CELL

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

(2018) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Gene therapy comes of age

(2018) Cynthia E. Dunbar et al.   SCIENCE

Cytokine release syndrome: grading, modeling, and new therapy

(2018) Delong Liu et al.   Journal of Hematology & Oncology

Universal CARs, universal T cells, and universal CAR T cells

(2018) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

(2018) Zihai Li et al.   Journal of Hematology & Oncology

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

(2017) Iulia Diaconu et al.   MOLECULAR THERAPY

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

(2017) Kevin Bielamowicz et al.   NEURO-ONCOLOGY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

(2017) Anja Feldmann et al.   Oncotarget

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

(2017) Jason J. Lohmueller et al.   OncoImmunology

Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model

(2017) Elham Pishali Bejestani et al.   OncoImmunology

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Improving the safety of T-Cell therapies using an inducible caspase-9 gene

(2016) Xiaoou Zhou et al.   EXPERIMENTAL HEMATOLOGY

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

Versatile strategy for controlling the specificity and activity of engineered T cells

(2016) Jennifer S. Y. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

(2016) David T. Rodgers et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches

(2016) Guoliang Ding et al.   Science China-Life Sciences

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules

(2015) Min Soo Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells

(2014) Marc Cartellieri et al.   PLoS One

Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system

(2014) Claudia Arndt et al.   PROSTATE

Protein conjugation with genetically encoded unnatural amino acids

(2013) Chan Hyuk Kim et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B

(2013) Stefanie Koristka et al.   JOURNAL OF AUTOIMMUNITY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor

(2012) K. Urbanska et al.   CANCER RESEARCH

Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

(2012) K. Tamada et al.   CLINICAL CANCER RESEARCH

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Structural basis of RNA binding by leucine zipper GCN4

(2012) Yaroslav Nikolaev et al.   PROTEIN SCIENCE

Development of a novel universal immune receptor for antigen targeting

(2012) Katarzyna Urbanska et al.   OncoImmunology

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

(2012) Daniel J O’Shannessy et al.   SpringerPlus

Folate receptor α: A storied past and promising future in immunotherapy

(2011) Guy T. Clifton et al.   Human vaccines & immunotherapeutics

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Folate-Targeted Therapies for Cancer

(2010) Wei Xia et al.   JOURNAL OF MEDICINAL CHEMISTRY